Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Study of the bioaccumulation of tinzaparin in renally impaired patients when given at prophylactic doses - The STRIP study.

Thrombosis research·2018
Same author

Mild bleeding disorders: what every clinician should know.

British journal of hospital medicine (London, England : 2005)·2017
Same author

Comparison of multiple electrode aggregometry with lumi-aggregometry for the diagnosis of patients with mild bleeding disorders.

Journal of thrombosis and haemostasis : JTH·2017
Same author

Clustering of glycoprotein VI (GPVI) dimers upon adhesion to collagen as a mechanism to regulate GPVI signaling in platelets.

Journal of thrombosis and haemostasis : JTH·2017
Same author

The Effects of Different Aspirin Dosing Frequencies and the Timing of Aspirin Intake in Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review.

Clinical pharmacology and therapeutics·2016
Same author

An atypical IgM class platelet cold agglutinin induces GPVI-dependent aggregation of human platelets.

Thrombosis and haemostasis·2015

Related Experiment Video

Updated: May 13, 2026

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

Genotyping and phenotyping of platelet function disorders.

S P Watson1, G C Lowe, M Lordkipanidzé

  • 1Centre for Cardiovascular Sciences, Institute of Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. s.p.watson@bham.ac.uk

Journal of Thrombosis and Haemostasis : JTH
|March 23, 2013
PubMed
Summary

Platelet function disorders (PFDs) present diagnostic challenges. This study identified functional defects and mutations in ~60% of patients, highlighting the complexity of bleeding disorders.

Keywords:
bleedingblood platelet disordersdeep sequencingplatelet aggregationplatelets

More Related Videos

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Experiment Videos

Last Updated: May 13, 2026

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Area of Science:

  • Hematology
  • Genetics
  • Molecular Biology

Background:

  • Platelet function disorders (PFDs) often cause mild bleeding but pose significant hemorrhage risk during trauma or surgery.
  • Current diagnostic assays for PFDs are complex, time-consuming, and subject to inter-laboratory variability.
  • Similar mucocutaneous bleeding patterns occur in other hemostatic disorders, like von Willebrand disease (VWD).

Purpose of the Study:

  • To investigate the genetic and functional basis of excessive bleeding in patients diagnosed with PFDs.
  • To identify causative mutations and understand the etiology of bleeding symptoms in a challenging patient cohort.

Main Methods:

  • Utilized lumi-aggregometry, specialized platelet function tests, Sanger sequencing, and next-generation sequencing (NGS).
  • Conducted extensive genotyping and platelet phenotyping on patients with clinically diagnosed excessive bleeding.

Main Results:

  • Identified functional defects in approximately 60% of patients, often linked to platelet activation feedback pathways.
  • Discovered function-disrupting mutations in both known and novel genes.
  • Demonstrated coinheritance of PFDs with other hemostatic disorders, such as type 1 VWD.
  • Observed that many identified mutations are heterozygous, suggesting incomplete penetrance and multifactorial causes for bleeding.

Conclusions:

  • Mucocutaneous bleeding is a complex trait influenced by multiple genetic and potentially environmental factors.
  • NGS plays a crucial role in assessing PFDs, especially given the identification of novel mutations and heterozygous variants.
  • Understanding the genetic heterogeneity and multifactorial nature of PFDs is essential for accurate diagnosis and management.